Switching to Retatrutide from Tirzepatide or Semaglutide

This article covers what we know about switching between GLP-1 class drugs generally, why people are interested in retatrutide specifically, and how to find clinical trials if you want to explore access before approval.

Why People Want to Switch

People often ask about switching after a weight-loss plateau or persistent side effects. Retatrutide has reported substantial weight loss, but these separate trials cannot tell someone how much additional weight they would lose after switching:

Retatrutide adds glucagon-receptor activity to GLP-1 and GIP activity. Its trials do not isolate how much weight loss each receptor contributes, and results in people beginning a study do not establish a benefit for people already taking another incretin drug.

Current Status: Not Available Outside Clinical Trials

What We Know About Switching Between GLP-1 Drugs

While no retatrutide-specific switching data exists, there is established clinical experience with switching between existing GLP-1 receptor agonists. Here is what that experience tells us:

The gap between drugs depends on the treatment

A schedule used to switch between two approved drugs cannot be assumed to work for retatrutide. Symptoms, the current drug’s persistence, other medicines, and a trial’s eligibility rules can change the timing. A trial washout is a study requirement, not a general recommendation to stop treatment for that length of time.

Dose titration usually restarts

Milligrams are not interchangeable across semaglutide, tirzepatide, and retatrutide. Prior tolerance of a high dose does not establish a safe retatrutide starting dose. Any transition in a study must follow its protocol and study team; there is no evidence-based conversion to publish for routine care.

GI side effects may recur

Even if a patient has adapted to GI side effects on their current medication, switching to a new drug — especially one with a different receptor profile — may trigger a new round of nausea, diarrhea, or other GI symptoms during the titration phase.

Each drug has a different receptor profile

This is particularly relevant for a hypothetical switch to retatrutide:

A patient switching from semaglutide to retatrutide would be adding two entirely new receptor activations (GIP and glucagon). A patient switching from tirzepatide would be adding one (glucagon). The glucagon component in particular could introduce new physiological effects — potential benefits and side effects. Receptor differences alone do not predict an individual’s response or establish a transition schedule.

How to Access Retatrutide Through Clinical Trials

Investigational access is through clinical research. Recruitment varies by study and site; do not stop a prescribed medicine to qualify before speaking with the study team.

How to search for trials

1. ClinicalTrials.gov — Search for "retatrutide" on ClinicalTrials.gov to see all registered trials, their locations, and eligibility criteria.
2. Lilly Trial Finder — Visit LillyTrialGuide.com for Eli Lilly's own trial search tool.
3. Ask your doctor — Your physician can help determine if you meet eligibility criteria and refer you to a participating trial site.

What to expect

• Clinical trial participants receive the study drug at no cost
• You may be randomized to placebo — there is no guarantee you will receive retatrutide
• Participants are monitored with regular medical visits, blood work, and assessments
• Prior and current weight-loss medicines can affect eligibility. The study team must confirm any exclusion interval and coordinate changes with your prescriber.

What Happens After Approval

If retatrutide is approved, its label, transition studies, and clinical experience will guide prescribing. Approval itself would not prove a benefit from switching. At that point, the decision to switch will involve:

• Evaluating your response to current therapy — if you are achieving good results on semaglutide or tirzepatide, switching may not be necessary
• Discussing potential benefits — consider evidence for your diagnosis and treatment history; plateau-specific benefits have not been established
• Insurance and cost considerations — a new brand-name drug will likely have different coverage than established medications, and coverage would need to be checked at that time
• Titration planning — you and your doctor will need to plan the transition, including when to stop the current drug and how to titrate the new one

Frequently Asked Questions

Sources

• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Eli Lilly and Company. (2025). Lilly's retatrutide achieved significant weight loss and pain relief in adults with obesity and knee osteoarthritis. Press release.
• Giblin, M.J., et al. (2026). Design of the TRIUMPH Phase 3 program for retatrutide in obesity. Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.70209
• ClinicalTrials.gov: Retatrutide trials, TRIUMPH-4 (NCT05929066)